ProKidney Will Present Eight Research Abstracts
The company will share data on its rilparencel drug candidate at the 2026 ASN Kidney Week conference in Denver.
Updated on Oct. 2, 2026 in Diabetes
Live Poll
Will upcoming kidney research presentations provide clear evidence of real-world patient benefit?
ProKidney plans to present eight research abstracts at the American Society of Nephrology's Kidney Week, occurring from October 21 to October 25, 2026. These presentations will detail studies involving the drug candidate rilparencel.
Why it matters
The company intends to provide evidence supporting the multifactorial mechanism of action for rilparencel. These findings offer insight into the treatment of advanced chronic kidney disease in patients with type 2 diabetes.
ProKidney is presenting results from Phase 2 analyses and translational studies. The presentations focus on patients meeting Phase 3 eligibility criteria, aiming to demonstrate kidney function stabilization.
The players
ProKidney
This biotechnology company focuses on developing cell-based therapies to treat chronic kidney disease.
American Society of Nephrology
This professional organization is dedicated to advancing kidney health through research, education, and advocacy.
The details
Researchers performed translational model studies and drug product characterization to better understand rilparencel. The presentations include a pooled Phase 2 analysis of patients who meet the criteria established for the ongoing PROACT 1 clinical study.
Timeline
October 21-25, 2026: American Society of Nephrology's Kidney Week in Denver, Colorado.
October 22, 2026: Two poster presentations are scheduled.
October 23, 2026: One oral presentation and two poster presentations will take place.
October 24, 2026: Three additional poster presentations are scheduled.
Deeper Dive
The ASN Kidney Week conference represents the premier annual forum for nephrology research, dictating the pace at which new therapies enter the standard clinical dialogue. By securing these presentations, ProKidney aligns its progress with the current academic and clinical benchmarks set by the society.
The clinical results regarding rilparencel provide insight into potential future treatment options for those managing both type 2 diabetes and advanced chronic kidney disease. These developments highlight the ongoing search for therapies that can effectively stabilize kidney function.
The takeaway
Advancements in translational research for chronic conditions often rely on large conferences for peer verification and industry awareness. Patients and providers should monitor these findings for their potential to influence future standard-of-care protocols.
What happens next
ProKidney expects its current cash reserves to be sufficient to support its operational plans through the middle of 2027.
Further reading
Learn more about the latest research in this field on the Diabetes page.
More information
View the specific research papers by visiting the ASN Kidney Week abstract search.
Live Poll
Will upcoming kidney research presentations provide clear evidence of real-world patient benefit?
